07 November 2019
Visiongain has launched a new pharma report Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029 : Mammalian Cell Cultures, Microbial Fermentations, and Other Expression Systems; Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines, and Others Therapeutic Areas.
The growth of the biosimilars market in the EU and the rise of generics will have a big effect on the biotech manufacturing services market. Consolidation as a strategy gives not only manufacturing capabilities, but access to cutting-edge technology and helps foster and establish relationships that can be used to enter new markets. Outsourcing as a strategy to reduce costs and increase efficiency can be a strength for biopharmaceutical companies. This trend in outsourcing will shift from the traditional model of using EU and US CMOs to outsourcing from lower emerging market CMOs, especially in Asia.
The lead analyst of the report commented "Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes. This demand will continue to rise in the coming 10 years, Visiongain believes. CMOs can offer significant advantages in terms of cost and manufacturing flexibility for companies. Additionally, with many CMOs in the market, the range of services available to pharma companies is broad - CMOs have many opportunities to appeal to these pharma clients. CMOs can choose to specialise, providing a niche service or expertise in a particular formulation."
Leading companies featured in the report include Boehringer Ingelheim Abbvie, Boehringer Ingelheim BioXcellence, Catalent, Celltrion, Cytovance Biologics and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.